Liminatus Pharma, Inc. (LIMNW)

The security is trapped in a severe liquidity and solvency crisis, making it a dangerous speculative vehicle rather than an investment. The price has collapsed to its 52-week low of $0.0451, indicating a complete loss of market confidence, while the company burns through significant cash with negative operating and free cash flows, leaving no runway for operations without further dilution. The balance sheet is critically impaired, with debt-to-equity soaring to nearly 480x and a book value so low ($0.005) that the current trading price is nine times the net asset value—a clear signal that the market sees no intrinsic value remaining. With no analyst coverage, no dividend history, and a lack of recent price anchors to suggest any recovery trend, the instrument offers no margin of safety and presents a high probability of further erosion or delisting.